Muscle creatine kinase/SV40 hybrid promoter for muscle-targeted long-term transgene expression

International Journal of Molecular Medicine

Volumn 19, Issue 2, 2007, Pages 309-315

  Takeshita, Fumihiko ^a   Takase, Keiko ^a   Tozuka, Miyuki ^a   Saha, Sukumar ^a   Okuda, Kenji ^a   Ishii, Norihisa ^b   Sasaki, Shin ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Creatine kinase; SV40 hybrid promoter; Transgene expression

Indexed keywords

CREATINE KINASE MM;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL LINE; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOGENETICS; METABOLISM; MOUSE; PROMOTER REGION; PROTEIN ENGINEERING; SIMIAN VIRUS 40; TIME; TRANSGENE;

ANIMALS; CELL LINE; CREATINE KINASE, MM FORM; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOGENETICS; MICE; MICE, INBRED BALB C; PROMOTER REGIONS (GENETICS); PROTEIN ENGINEERING; SIMIAN VIRUS 40; TIME FACTORS; TRANSGENES;

EID: 33847780327     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Lu QL, Bou-Gharios G and Partridge TA: Non-viral gene delivery in skeletal muscle: a protein factory. Gene Ther 10: 131-142, 2003.
2. Herweijer H and Wolff JA: Progress and prospects: naked DNA gene transfer and therapy. Gene Ther 10: 453-458, 2003.
3. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A and Felgner PL: Direct gene transfer into mouse muscle in vivo. Science 247: 1465-1468, 1990.
4. Chuah MK, Collen D and Van den Driessche T: Gene therapy for hemophilia. J Gene Med 3: 3-20, 2001.
5. Bohl D and Heard JM: Delivering erythropoietin through genetically engineered cells. J Am Soc Nephrol 11: S159-S162, 2000.
6. Kreiss P, Bettan M, Crouzet J and Scherman D: Erythropoietin secretion and physiological effect in mouse after intramuscular plasmid DNA electrotransfer. J Gene Med 1: 245-250, 1999.
7. Chamberlain JS: Gene therapy of muscular dystrophy. Hum Mol Genet 11: 2355-2362, 2002.
8. MacColl GS, Novo FJ, Marshall NJ, Waters M, Goldspink G and Bouloux PM: Optimisation of growth hormone production by muscle cells using plasmid DNA. J Endocrinol 165: 329-336, 2000.
9. Cheng SH and Smith AE: Gene therapy progress and prospects: gene therapy of lysosomal storage disorders. Gene Ther 10: 1275-1281, 2003.
10. Boshart M, Weber F, Jahn G, Dorsch-Hasler K, Fleckenstein B and Schaffner W: A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell 41: 521-530, 1985.
11. Miyazaki J, Takaki S, Araki K, Tashiro F, Tominaga A, Takatsu K and Yamamura K: Expression vector system based on the chicken beta-actin promoter directs efficient production of interleukin-5. Gene 79: 269-277, 1989.
12. Bloquel C, Fabre E, Bureau MF and Scherman D: Plasmid DNA electrotransfer for intracellular and secreted proteins expression: new methodological developments and applications. J Gene Med 6: S11-S23, 2004.
13. Smith LC and Nordstrom JL: Advances in plasmid gene delivery and expression in skeletal muscle. Curr Opin Mol Ther 2: 150-154, 2000.
14. Payette PJ, Weeratna RD, McCluskie MJ and Davis HL: Immune-mediated destruction of transfected myocytes following DNA vaccination occurs via multiple mechanisms. Gene Ther 8: 1395-1400, 2001.
15. Gronevik E, von Steyern FV, Kalhovde JM, Tjelle TE and Mathiesen I: Gene expression and immune response kinetics using electroporation-mediated DNA delivery to muscle. J Gene Med 7: 218-227, 2005.
16. Bettan M, Emmanuel F, Darteil R, Caillaud JM, Soubrier F, Delaere P, Branelec D, Mahfoudi A, Duverger N and Scherman D: High-level protein secretion into blood circulation after electric pulse-mediated gene transfer into skeletal muscle. Mol Ther 2: 204-210, 2000.
17. Ghazizadeh S, Kalish RS and Taichman LB: Immune-mediated loss of transgene expression in skin: implications for cutaneous gene therapy. Mol Ther 7: 296-303, 2003.
18. Bettan M, Darteil R and Scherman D: Secreted human placental alkaline phosphatase as a reporter gene for in vivo gene transfer. Anal Biochem 271: 187-189, 1999.
19. Chenuaud P, Larcher T, Rabinowitz JE, Provost N, Cherel Y, Casadevall N, Samulski RJ and Moullier P: Autoimmune anemia in macaques following erythropoietin gene therapy. Blood 103: 3303-3304, 2004.
20. Wu H, Reding M, Qian J, Okita DK, Parker E, Lollar P, Hoyer LW and Conti-Fine BM: Mechanism of the immune response to human factor VIII in murine hemophilia A. Thromb Haemost 85: 125-133, 2001.
21. Dunant P, Larochelle N, Thirion C, Stucka R, Ursu D, Petrof BJ, Wolf E and Lochmuller H: Expression of dystrophin driven by the 1.35-kb MCK promoter ameliorates muscular dystrophy in fast, but not in slow muscles of transgenic mdx mice. Mol Ther 8: 80-89, 2003.
22. Yoshimura M, Sakamoto M, Ikemoto M, Mochizuki Y, Yuasa K, Miyagoe-Suzuki Y and Takeda S: AAV vector-mediated micro-dystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype. Mol Ther 10: 821-828, 2004.
23. Weeratna RD, Wu T, Efler SM, Zhang L and Davis HL: Designing gene therapy vectors: avoiding immune responses by using tissue-specific promoters. Gene Ther 8: 1872-1878, 2001.
24. Sasaki S, Amara RR, Oran AE, Smith JM and Robinson HL: Apoptosis-mediated enhancement of DNA-raised immune responses by mutant caspases. Nat Biotechnol 19: 543-547, 2001.
25. Donoviel DB, Shield MA, Buskin JN, Haugen HS, Clegg CH and Hauschka SD: Analysis of muscle creatine kinase gene regulatory elements in skeletal and cardiac muscles of transgenic mice. Mol Cell Biol 16: 1649-1658, 1996.
26. Wang M, Orsini C, Casanova D, Millan JL, Mahfoudi A and Thuillier V: MUSEAP, a novel reporter gene for the study of long-term gene expression in immunocompetent mice. Gene 279: 99-108, 2001.
27. Liu F, Song Y and Liu D: Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 6: 1258-1266, 1999.
28. Gronevik E, Mathiesen I and Lomo T: Early events of electroporation- mediated intramuscular DNA vaccination potentiate Th1-directed immune responses. J Gene Med 7: 1246-1254, 2005.
29. Chastain M, Simon AJ, Soper KA, Holder DJ, Montgomery DL, Sagar SL, Casimiro DR and Middaugh CR: Antigen levels and antibody titers after DNA vaccination. J Pharm Sci 90: 474-484, 2001.
30. Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, Izykowski B, Phillips J, Doroshow R, Walot I, Hoft R and Neufeld EF: Enzyme-replacement therapy in muco-polysaccharidosis I. N Engl J Med 344: 182-188, 2001.
31. Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, Gass A, Winston J, Dikman S, Fallon JT, Broide S, Stacy CB, Mehta D, Parsons R, Norton K, O'Callagham M and Desnick RJ: A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68: 711-722, 2001.
32. Scharrer I, Bray GL and Neutzling O: Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 5: 145-154, 1999.
33. Garg S, Oran AE, Hon H and Jacob J: The hybrid cytomegalo-virus enhancer/chicken beta-actin promoter along with woodchuck hepatitis virus posttranscriptional regulatory element enhances the protective efficacy of DNA vaccines. J Immunol 173: 550-558, 2004.
34. Walsh C: Gene therapy for hemophilia: are viral vectors really feasible? J Thromb Haemost 1: 218-219, 2003.
35. Yew NS, Przybylska M, Ziegler RJ, Liu D and Cheng SH: High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter. Mol Ther 4: 75-82, 2001.
36. Chaffee S, Mary A, Stiehm ER, Girault D, Fischer A and Hershfield MS: IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. J Clin Invest 89: 1643-1651, 1992.
37. Richards SM, Olson TA and McPherson JM: Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase. Blood 82: 1402-1409, 1993.
38. Chen YT and Amalfitano A: Towards a molecular therapy for glycogen storage disease type II (Pompe disease). Mol Med Today 6: 245-251, 2000.
39. Torres CA, Iwasaki A, Barber BH and Robinson HL: Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations. J Immunol 158: 4529-4532, 1997.
40. Takeshita F, Tanaka T, Matsuda T, Tozuka M, Kobiyama K, Saha S, Matsui K, Ishii KJ, Coban C, Akira S, Ishii N, Suzuki K, Klinman DM, Okuda K and Sasaki S: Toll-like receptor adaptor molecules enhance DNA-raised adaptive immune responses against influenza and tumors through activation of innate immunity. J Virol 80: 6218-6224, 2006.
41. Sasaki S, Smith JM, Takase K, Okuda K, Ishii N and Takeshita F: Activator protein 1-mediated transcriptional regulation strategy sustains long-term expression of a xenogeneic gene product in vivo: an implication for gene therapy targeting congenital protein deficiencies. Int J Mol Med 18: 289-297, 2006.
42. Maelandsmo GM, Ross PJ, Pavliv M, Meulenbroek RA, Evelegh C, Muruve DA, Graham FL and Parks RJ: Use of a murine secreted alkaline phosphatase as a non-immunogenic reporter gene in mice. J Gene Med 7: 307-315, 2005.
43. Sarkar R, Gao GP, Chirmule N, Tazelaar J and Kazazian HH: Partial correction of murine hemophilia A with neo-antigenic murine factor VIII. Hum Gene Ther 11: 881-894, 2000. (Pubitemid 30202479)
44. Qian J, Collins M, Sharpe AH and Hoyer LW: Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood 95: 1324-1329, 2000.
45. Fields PA, Kowalczyk DW, Arruda VR, Armstrong E, McCleland ML, Hagstrom JN, Pasi KJ, Ertl HC, Herzog RW and High KA: Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol Ther 1: 225-235, 2000.
46. Herzog RW, Fields PA, Arruda VR, Brubaker JC, Armstrong E, McClintock D, Bellinger DA, Couto LB, Nichols TC and High KA: Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum Gene Ther 13: 1281-1291, 2002.
47. Gao G, Lebherz C, Weiner DJ, Grant R, McCullough B, Calcedo R, Bagg A, Zhang Y and Wilson JM: Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood 103: 3300-3302, 2004.